Denmark-based clinical-stage biotech company NMD Pharma A/S announced on Tuesday that it has secured US Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) application to initiate a Phase 2 trial (SYNAPSE-CMT) of NMD670, a first-in-class muscle-targeted therapy, in patients with Charcot-Marie-Tooth (CMT) type 1 and 2.
The randomised, double-blind, placebo-controlled trial will assess the safety, efficacy and tolerability of NMD670 in around 80 adult patients across the United States and Europe. Expected to begin enrolment soon, the 21-day trial will evaluate endpoints including 6-minute walk test and timed-up-and-go test.
This follows NMD Pharma's announcement of positive results from the ESTABLISH study in June 2023, highlighting neuromuscular junction dysfunction as a characteristic in CMT patients.
SYNAPSE-CMT joins two ongoing Phase 2 trials of NMD670 for spinal muscular atrophy (SMA) type 3 and generalised myasthenia gravis, solidifying NMD Pharma's focus on rare neuromuscular diseases.
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Avacta Group partners with Tempus to enhance AI-driven oncology drug development
PharmaLogic opens new radiopharmaceutical facility in Salt Lake City
Astellas Pharma's VYLOY receives US FDA approval
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Elysium Health launches VISION for visual performance and eye health
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
Innovent Biologic meets primary endpoint in picankibart phase 2 study